Gerald F. Watts

发表

Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study

Jennifer G. Robinson, J. D. Jordan, G. Molenberghs, 2016, Journal of the American Heart Association.

Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Med

F. Kronenberg, J. Borén, A. von Eckardstein, 2016, Clinical chemistry.

Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel.

S. Humphries, S. Yamashita, G. Watts, 2016, The lancet. Diabetes & endocrinology.

Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM

F. Kronenberg, J. Borén, A. von Eckardstein, 2019, Clinical chemistry and laboratory medicine.

A consensus statement from the European Atherosclerosis Society Consensus Panel

B. Sluis, A. Catapano, B. Ference, 2018 .

Low-density lipoproteins cause atherosclerotic cardiovascular disease.1. Evidence from genetic, epidemiologic, and clinical studies

B. Sluis, A. Catapano, B. Ference, 2018 .

Evidence from A from

B. Sluis, A. Catapano, B. Ference, 2017 .

RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia.

C. Ballantyne, S. Thackwray, Ting Chang, 2023, NEJM evidence.

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).

J. Car, E. Mirrakhimov, A. Sahebkar, 2018, Atherosclerosis.

Familial hypercholesterolaemia: A global call to arms.

J. Car, A. Sahebkar, G. Latkovskis, 2015, Atherosclerosis.

The Role of Nutraceuticals in Statin Intolerant Patients

D. Panagiotakos, A. Sahebkar, G. Latkovskis, 2018 .

Review the Polygenic Nature of Hypertriglyceridaemia: Implications for Defi Nition, Diagnosis, and Management

J. Borén, S. Humphries, M. Taskinen, 2022 .

[Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society].

P. Pajukanta, A. Tybjaerg-hansen, J. Kuivenhoven, 2015, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

Familial lipoprotein lipase (LPL) deficiency: A catalogue of LPL gene mutations identified in 20 patients from the UK, Sweden, and Italy

P. Talmud, H. Lithell, D. Muller, 1997, Human mutation.

Age- and sex-based heterogeneity in coronary artery plaque presence and burden in familial hypercholesterolemia: A multi-national study

Gowtham R. Grandhi, Reed Mszar, M. Cainzos‐Achirica, 2023, American journal of preventive cardiology.

Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis.

A. Henney, G. Watts, S. Ye, 1994, British heart journal.

Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study

N. Antonio-Villa, A. Vargas-Vázquez, J. Jozwiak, 2023, The Lancet.

Chylomicron remnant metabolism in familial hypercholesterolaemia studied with a stable isotope breath test.

G. Watts, S. Dimmitt, A. Marais, 2001, Atherosclerosis.